Drug Profile
Research programme: antibacterials - Crucell/AstraZeneca
Latest Information Update: 09 Aug 2021
Price :
$50
*
At a glance
- Originator Crucell
- Developer Crucell; MedImmune
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 28 Mar 2008 Preclinical development is ongoing
- 15 Oct 2007 Preclinical development is ongoing
- 15 Oct 2007 Antibodies from one of Crucell's MAbstract® technology programmes for hospital-acquired bacterial infection licensed to MedImmune